TITLE: AMINOGLYCOSIDE EXTENDED INTERVAL DOSING AND MONITORING IN ADULTS

PURPOSE:
These recommendations were developed by the NewYork-Presbyterian Hospital – Columbia and Weill Cornell Medical Centers’ Division of Infectious Diseases and Department of Pharmacy to aid prescribers and pharmacy personnel in the selection, dosing, and monitoring of extended interval (“once daily”) dosing of aminoglycosides.

APPLICABILITY:
All Centers

PROCEDURE:
This is an alternative dosing method which may be less nephrotoxic than conventional dosing with similar efficacy. The higher peak concentrations achieved with this high-dose method may result in a more rapid killing of organisms due to the concentration-dependent killing observed with aminoglycosides. The lower trough concentrations may result in a potentially lower incidence of toxicity.

Single-daily high dose aminoglycoside therapy should not be confused with patients receiving conventional dosing methods (1 to 2 mg/kg/day) for whom the dosing interval has been adjusted to every 24 hours because of renal dysfunction.

The following are conservative guidelines for the selection, dosing, and monitoring of extended interval (“once daily”) dosing of aminoglycosides adapted from published pharmacokinetic and pharmacodynamic literature.

Exclusion criteria:
- Elderly (age ≥ 70 years)
- Pregnancy or post-partum
- Renal insufficiency (CrCL< 30 ml/min)
- Dialysis
- Severe liver disease or ascites
- History or signs of hearing loss or vestibular toxicity
- Endocarditis
- Synergy for gram positive infections
- Cystic fibrosis
- Surgical prophylaxis
- Severe fluid overload states
- Extensive burns (> 50% total body surface area)
IMPORTANT: DO NOT USE TOTAL BODY WEIGHT UNLESS PATIENT’S ACTUAL WEIGHT IS LESS THAN THEIR IDEAL WEIGHT

1. Determine patient’s dosing weight (DW)
   a. Non-Obese patients: Use ideal body weight (IBW) unless total body weight (TBW) is less. Non-obese is defined as TBW < 30% over ideal body weight
      - IBW (males) = 50 kg + (2.3 x height in inches > 60 inches)
      - IBW (females) = 45 kg + (2.3 x height in inches > 60 inches)
   b. Obese patients: Use adjusted body weight (ABW) in obese patients (TBW > 30% over IBW)
      - ABW (kg) = IBW + 0.4 (TBW – IBW)

2. Determine patient’s dose
   (round to nearest 20 mg for gentamicin/tobramycin and to nearest 100 mg for amikacin)
   - Gentamicin / Tobramycin 5 to 7 mg/kg x DW
   - Amikacin 15 to 20 mg/kg x DW

3. Estimate patient’s creatinine clearance (CrCL)
   - CrCL (male) ml/min = (140 - age) x DW (kg) / 72 x SCr
     (Use minimum SCr of 1 mg/dL. Certain disease states or other factors may alter the relationship between SCr and CrCL resulting in over- or under-estimation of CrCL)
   - CrCL (females) ml/min = CrCL (male) x 0.85

4. Determine patient’s dosing interval based on CrCL
   
<table>
<thead>
<tr>
<th>CrCL (ml/min)</th>
<th>Interval (hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 50</td>
<td>q24h</td>
</tr>
<tr>
<td>30 – 50</td>
<td>q36h</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>Not eligible, use conventional dosing</td>
</tr>
</tbody>
</table>

5. Serum concentration monitoring

   Use trough levels (peak levels NOT routinely monitored):
   - Trough concentrations should be checked 30 to 60 minutes prior to the next (second) dose. Desired levels:
     - Gentamicin / tobramycin < 0.5 mcg/mL
     - Amikacin < 2.5 mcg/mL
   - If level is greater than desired trough, extend dosing interval by 12 hours and repeat level prior to next dose (or use conventional dosing and monitoring methods). If the next level continues to be high, then change to conventional dosing method.
   - Repeat level weekly AND with any significant changes in renal function. Serum creatinine should be monitored every 1-3 days
RESPONSIBILITY:
Joint Subcommittee on Anti-Infective Use

POLICY/GUIDELINE DATES:
Issued: October 2005
Reviewed: May 2010
Revised: March 2006
Medical Board Approval: March 2006